---
document_datetime: 2025-12-02 04:56:45
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/zydelig.html
document_name: zydelig.html
version: success
processing_time: 0.135718
conversion_datetime: 2025-12-28 12:27:23.895742
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Zydelig

[RSS](/en/individual-human-medicine.xml/65978)

##### Authorised

This medicine is authorised for use in the European Union

idelalisib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Zydelig](#news-on)
- [More information on Zydelig](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Zydelig is a cancer medicine that is used to treat chronic lymphocytic leukaemia (CLL, a cancer of a type of white blood cells called B lymphocytes) and follicular lymphoma (another cancer that affects B lymphocytes).

In CLL, Zydelig is used in combination with another medicine (rituximab or ofatumumab) in patients who have received at least one previous treatment and in patients whose cancer cells have genetic mutations (changes) called 17p deletion or TP53 mutation and who cannot be treated with any other therapy.

In follicular lymphoma, Zydelig is used on its own in patients whose disease has not improved with two previous treatments.

Zydelig contains the active substance idelalisib.

Expand section

Collapse section

## How is Zydelig used?

Zydelig can only be obtained with a prescription and it should be prescribed by a doctor experienced in using cancer medicines.

Zydelig is available as 100 mg and 150 mg tablets. The recommended dose is 150 mg twice a day, and treatment should be continued for as long as the patient improves or remains stable and the side effects are tolerable. If the patient has severe side effects, treatment must be stopped and can be re-started at a lower dose of 100 mg twice a day.

All patients treated with Zydelig should also be given preventive medication against the lung infection Pneumocystis jirovecii pneumonia, and this should be continued for up to 6 months after stopping treatment with Zydelig. Patients should also be monitored for infection and have regular blood tests to measure the level of white blood cells. Zydelig should not be started in patients with any generalised infection (infection that has spread with symptoms affecting the whole body, such as fever and chills).

For more information about using Zydelig, see the package leaflet or contact your doctor or pharmacist.

## How does Zydelig work?

The active substance in Zydelig, idelalisib, blocks the effects of an enzyme called PI3K-delta. This enzyme plays a role in the growth, migration and survival of white blood cells but is overactive in blood cancers, where it enables the survival of the cancer cells. By targeting this enzyme and blocking its effects, idelalisib causes death of the cancer cells, thereby delaying or stopping the progression of the cancer.

## What benefits of Zydelig have been shown in studies?

In a main study of 220 patients with previously treated CLL, Zydelig was more effective at treating the cancer than placebo (a dummy treatment) when both were given in combination with rituximab: 75% of patients taking Zydelig had an improvement in their disease compared with 15% of patients receiving placebo. Zydelig was also more effective than placebo in patients who had a specific genetic mutation in their cancer cells that makes them unsuitable for certain other therapies.

Zydelig with ofatumumab was more effective than ofatumumab alone in the treatment of CLL. In a study of 261 previously treated CLL patients, it took over 16 months on average before the disease got worse in patients treated with Zydelig plus ofatumumab, compared with 8 months in those treated with ofatumumab alone.

Another main study evaluated Zydelig in patients with different lymphomas, including 72 patients with follicular lymphoma that had failed two previous treatments. Zydelig was effective, with 54% of patients with follicular lymphoma having either a complete or partial response to treatment.

## What are the risks associated with Zydelig?

The most common side effects with Zydelig (which may affect more than 1 in 10 people) are infections (including lung infection caused by Pneumocystis jirovecii, and cytomegalovirus infections), neutropenia (low levels of neutrophils, a type of white blood cell), lymphocytosis (increased levels of lymphocytes, another type of white blood cell), diarrhoea, blood tests showing changes in the liver, rash, fever and increased blood fat levels.

For the full list of side effects  and restrictions of Zydelig, see the package leaflet.

## Why is Zydelig authorised in the EU?

The European Medicines Agency noted that data from the main studies showed high response rates with Zydelig in patients with chronic lymphocytic leukaemia and follicular lymphoma. Zydelig was also effective in chronic lymphocytic leukaemia patients whose cancer cells have the 17p deletion or TP53 mutation, who usually have a poor outcome.

In addition, the safety of the medicine was considered acceptable. The Agency therefore concluded that Zydelig's benefits are greater than its risks and recommended that it be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Zydelig?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zydelig have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Zydelig are continuously monitored. Side effects reported with Zydelig are carefully evaluated and any necessary action taken to protect patients.

## Other information about Zydelig

Zydelig received a marketing authorisation valid throughout the EU on 18 September 2014.

Zydelig : EPAR - Medicine overview

English (EN) (131.82 KB - PDF)

**First published:** 14/10/2014

**Last updated:** 10/01/2020

[View](/en/documents/overview/zydelig-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-596)

български (BG) (140.26 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

10/01/2020

[View](/bg/documents/overview/zydelig-epar-medicine-overview_bg.pdf)

español (ES) (114.85 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

10/01/2020

[View](/es/documents/overview/zydelig-epar-medicine-overview_es.pdf)

čeština (CS) (136.93 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

10/01/2020

[View](/cs/documents/overview/zydelig-epar-medicine-overview_cs.pdf)

dansk (DA) (114.08 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

10/01/2020

[View](/da/documents/overview/zydelig-epar-medicine-overview_da.pdf)

Deutsch (DE) (117.69 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

10/01/2020

[View](/de/documents/overview/zydelig-epar-medicine-overview_de.pdf)

eesti keel (ET) (111.96 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

10/01/2020

[View](/et/documents/overview/zydelig-epar-medicine-overview_et.pdf)

ελληνικά (EL) (147.25 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

10/01/2020

[View](/el/documents/overview/zydelig-epar-medicine-overview_el.pdf)

français (FR) (116.56 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

10/01/2020

[View](/fr/documents/overview/zydelig-epar-medicine-overview_fr.pdf)

hrvatski (HR) (136.44 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

10/01/2020

[View](/hr/documents/overview/zydelig-epar-medicine-overview_hr.pdf)

italiano (IT) (113.65 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

10/01/2020

[View](/it/documents/overview/zydelig-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (145.49 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

10/01/2020

[View](/lv/documents/overview/zydelig-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (137.08 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

10/01/2020

[View](/lt/documents/overview/zydelig-epar-medicine-overview_lt.pdf)

magyar (HU) (136.21 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

10/01/2020

[View](/hu/documents/overview/zydelig-epar-medicine-overview_hu.pdf)

Malti (MT) (138.51 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

10/01/2020

[View](/mt/documents/overview/zydelig-epar-medicine-overview_mt.pdf)

Nederlands (NL) (113.96 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

10/01/2020

[View](/nl/documents/overview/zydelig-epar-medicine-overview_nl.pdf)

polski (PL) (139.02 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

10/01/2020

[View](/pl/documents/overview/zydelig-epar-medicine-overview_pl.pdf)

português (PT) (116.01 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

10/01/2020

[View](/pt/documents/overview/zydelig-epar-medicine-overview_pt.pdf)

română (RO) (136.94 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

10/01/2020

[View](/ro/documents/overview/zydelig-epar-medicine-overview_ro.pdf)

slovenčina (SK) (137.55 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

10/01/2020

[View](/sk/documents/overview/zydelig-epar-medicine-overview_sk.pdf)

slovenščina (SL) (135.18 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

10/01/2020

[View](/sl/documents/overview/zydelig-epar-medicine-overview_sl.pdf)

Suomi (FI) (113.36 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

10/01/2020

[View](/fi/documents/overview/zydelig-epar-medicine-overview_fi.pdf)

svenska (SV) (113.98 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

10/01/2020

[View](/sv/documents/overview/zydelig-epar-medicine-overview_sv.pdf)

Zydelig : EPAR - Risk-management-plan summary

English (EN) (79.16 KB - PDF)

**First published:** 14/10/2014

**Last updated:** 20/05/2021

[View](/en/documents/rmp-summary/zydelig-epar-risk-management-plan-summary_en.pdf)

## Product information

Zydelig : EPAR - Product information

English (EN) (420.57 KB - PDF)

**First published:** 14/10/2014

**Last updated:** 21/10/2024

[View](/en/documents/product-information/zydelig-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-525)

български (BG) (687.79 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

21/10/2024

[View](/bg/documents/product-information/zydelig-epar-product-information_bg.pdf)

español (ES) (451.69 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

21/10/2024

[View](/es/documents/product-information/zydelig-epar-product-information_es.pdf)

čeština (CS) (569.76 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

21/10/2024

[View](/cs/documents/product-information/zydelig-epar-product-information_cs.pdf)

dansk (DA) (394.16 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

21/10/2024

[View](/da/documents/product-information/zydelig-epar-product-information_da.pdf)

Deutsch (DE) (429.05 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

21/10/2024

[View](/de/documents/product-information/zydelig-epar-product-information_de.pdf)

eesti keel (ET) (405.6 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

21/10/2024

[View](/et/documents/product-information/zydelig-epar-product-information_et.pdf)

ελληνικά (EL) (546.29 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

21/10/2024

[View](/el/documents/product-information/zydelig-epar-product-information_el.pdf)

français (FR) (413.08 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

21/10/2024

[View](/fr/documents/product-information/zydelig-epar-product-information_fr.pdf)

hrvatski (HR) (501.14 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

21/10/2024

[View](/hr/documents/product-information/zydelig-epar-product-information_hr.pdf)

íslenska (IS) (388.63 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

21/10/2024

[View](/is/documents/product-information/zydelig-epar-product-information_is.pdf)

italiano (IT) (399.91 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

21/10/2024

[View](/it/documents/product-information/zydelig-epar-product-information_it.pdf)

latviešu valoda (LV) (503.36 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

21/10/2024

[View](/lv/documents/product-information/zydelig-epar-product-information_lv.pdf)

lietuvių kalba (LT) (533.82 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

21/10/2024

[View](/lt/documents/product-information/zydelig-epar-product-information_lt.pdf)

magyar (HU) (529.53 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

21/10/2024

[View](/hu/documents/product-information/zydelig-epar-product-information_hu.pdf)

Malti (MT) (541.13 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

21/10/2024

[View](/mt/documents/product-information/zydelig-epar-product-information_mt.pdf)

Nederlands (NL) (594.37 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

21/10/2024

[View](/nl/documents/product-information/zydelig-epar-product-information_nl.pdf)

norsk (NO) (423.5 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

21/10/2024

[View](/no/documents/product-information/zydelig-epar-product-information_no.pdf)

polski (PL) (547.87 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

21/10/2024

[View](/pl/documents/product-information/zydelig-epar-product-information_pl.pdf)

português (PT) (405.81 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

21/10/2024

[View](/pt/documents/product-information/zydelig-epar-product-information_pt.pdf)

română (RO) (456.17 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

21/10/2024

[View](/ro/documents/product-information/zydelig-epar-product-information_ro.pdf)

slovenčina (SK) (589.27 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

21/10/2024

[View](/sk/documents/product-information/zydelig-epar-product-information_sk.pdf)

slovenščina (SL) (483.87 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

21/10/2024

[View](/sl/documents/product-information/zydelig-epar-product-information_sl.pdf)

Suomi (FI) (440.16 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

21/10/2024

[View](/fi/documents/product-information/zydelig-epar-product-information_fi.pdf)

svenska (SV) (401.01 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

21/10/2024

[View](/sv/documents/product-information/zydelig-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0059 20/06/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Zydelig : EPAR - All Authorised presentations

English (EN) (19.98 KB - PDF)

**First published:** 14/10/2014

**Last updated:** 14/10/2014

[View](/en/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-214)

български (BG) (37.65 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/10/2014

[View](/bg/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_bg.pdf)

español (ES) (17.31 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/10/2014

[View](/es/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_es.pdf)

čeština (CS) (30.79 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/10/2014

[View](/cs/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (18.98 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/10/2014

[View](/da/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (17.19 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/10/2014

[View](/de/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (17.19 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/10/2014

[View](/et/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (38.11 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/10/2014

[View](/el/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_el.pdf)

français (FR) (17.21 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/10/2014

[View](/fr/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (29.88 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/10/2014

[View](/hr/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (17.05 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/10/2014

[View](/is/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_is.pdf)

italiano (IT) (17.24 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/10/2014

[View](/it/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (35.75 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/10/2014

[View](/lv/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (35.02 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/10/2014

[View](/lt/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (29.08 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/10/2014

[View](/hu/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (32.37 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/10/2014

[View](/mt/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (17.15 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/10/2014

[View](/nl/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (19.14 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/10/2014

[View](/no/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_no.pdf)

polski (PL) (27.31 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/10/2014

[View](/pl/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_pl.pdf)

português (PT) (19.16 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/10/2014

[View](/pt/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_pt.pdf)

română (RO) (31.85 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/10/2014

[View](/ro/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (32.49 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/10/2014

[View](/sk/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (25.2 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/10/2014

[View](/sl/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (17.1 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/10/2014

[View](/fi/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (19.16 KB - PDF)

**First published:**

14/10/2014

**Last updated:**

14/10/2014

[View](/sv/documents/all-authorised-presentations/zydelig-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Zydelig Active substance Idelalisib International non-proprietary name (INN) or common name idelalisib Therapeutic area (MeSH)

- Lymphoma, Non-Hodgkin
- Leukemia, Lymphocytic, Chronic, B-Cell

Anatomical therapeutic chemical (ATC) code L01XX47

### Pharmacotherapeutic group

- Antineoplastic agents
- Other antineoplastic agents

### Therapeutic indication

Zydelig is indicated in combination with an anti?CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL):

- who have received at least one prior therapy, or
- as first line treatment in the presence of 17p deletion or *TP53* mutation in patients who are not eligible for any other therapies.

Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.

## Authorisation details

EMA product number EMEA/H/C/003843

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Gilead Sciences Ireland UC

IDA Business &amp; Technology Park

Opinion adopted 25/07/2014 Marketing authorisation issued 18/09/2014 Revision 21

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Zydelig : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (252.05 KB - PDF)

**First published:** 22/05/2015

**Last updated:** 21/10/2024

[View](/en/documents/procedural-steps-after/zydelig-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Zydelig-H-C-3843-II-0032-G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/202018/2018

English (EN) (2.81 MB - PDF)

**First published:** 03/08/2018

**Last updated:** 03/08/2018

[View](/en/documents/variation-report/zydelig-h-c-3843-ii-0032-g-epar-assessment-report-variation_en.pdf)

Zydelig-H-C-PSUSA-00010303-201707 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/422302/2018

English (EN) (72.88 KB - PDF)

**First published:** 28/06/2018

**Last updated:** 28/06/2018

[View](/en/documents/scientific-conclusion/zydelig-h-c-psusa-00010303-201707-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Zydelig-H-C-10303-201701 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/694281/2017

English (EN) (82.06 KB - PDF)

**First published:** 14/12/2017

**Last updated:** 14/12/2017

[View](/en/documents/scientific-conclusion/zydelig-h-c-10303-201701-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Zydelig-H-C-003843-A20-1439-0023 : EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/586939/2016

English (EN) (392.17 KB - PDF)

**First published:** 21/11/2016

**Last updated:** 21/11/2016

[View](/en/documents/variation-report/zydelig-h-c-003843-a20-1439-0023-epar-assessment-report-article-20_en.pdf)

Zydelig : EPAR - Scientific conclusions

English (EN) (46.1 KB - PDF)

**First published:** 21/11/2016

**Last updated:** 21/11/2016

[View](/en/documents/scientific-conclusion/zydelig-epar-scientific-conclusions_en.pdf)

[Other languages (22)](#file-language-dropdown-353)

български (BG) (94.51 KB - PDF)

**First published:**

21/11/2016

**Last updated:**

21/11/2016

[View](/bg/documents/scientific-conclusion/zydelig-epar-scientific-conclusions_bg.pdf)

español (ES) (49.24 KB - PDF)

**First published:**

21/11/2016

**Last updated:**

21/11/2016

[View](/es/documents/scientific-conclusion/zydelig-epar-scientific-conclusions_es.pdf)

čeština (CS) (90.38 KB - PDF)

**First published:**

21/11/2016

**Last updated:**

21/11/2016

[View](/cs/documents/scientific-conclusion/zydelig-epar-scientific-conclusions_cs.pdf)

dansk (DA) (47.36 KB - PDF)

**First published:**

21/11/2016

**Last updated:**

21/11/2016

[View](/da/documents/scientific-conclusion/zydelig-epar-scientific-conclusions_da.pdf)

Deutsch (DE) (52.94 KB - PDF)

**First published:**

21/11/2016

**Last updated:**

21/11/2016

[View](/de/documents/scientific-conclusion/zydelig-epar-scientific-conclusions_de.pdf)

eesti keel (ET) (46.55 KB - PDF)

**First published:**

21/11/2016

**Last updated:**

21/11/2016

[View](/et/documents/scientific-conclusion/zydelig-epar-scientific-conclusions_et.pdf)

ελληνικά (EL) (98.26 KB - PDF)

**First published:**

21/11/2016

**Last updated:**

21/11/2016

[View](/el/documents/scientific-conclusion/zydelig-epar-scientific-conclusions_el.pdf)

français (FR) (51.26 KB - PDF)

**First published:**

21/11/2016

**Last updated:**

21/11/2016

[View](/fr/documents/scientific-conclusion/zydelig-epar-scientific-conclusions_fr.pdf)

hrvatski (HR) (84.33 KB - PDF)

**First published:**

21/11/2016

**Last updated:**

21/11/2016

[View](/hr/documents/scientific-conclusion/zydelig-epar-scientific-conclusions_hr.pdf)

italiano (IT) (47.06 KB - PDF)

**First published:**

21/11/2016

**Last updated:**

21/11/2016

[View](/it/documents/scientific-conclusion/zydelig-epar-scientific-conclusions_it.pdf)

latviešu valoda (LV) (89.42 KB - PDF)

**First published:**

21/11/2016

**Last updated:**

21/11/2016

[View](/lv/documents/scientific-conclusion/zydelig-epar-scientific-conclusions_lv.pdf)

lietuvių kalba (LT) (94.32 KB - PDF)

**First published:**

21/11/2016

**Last updated:**

21/11/2016

[View](/lt/documents/scientific-conclusion/zydelig-epar-scientific-conclusions_lt.pdf)

magyar (HU) (75.15 KB - PDF)

**First published:**

21/11/2016

**Last updated:**

21/11/2016

[View](/hu/documents/scientific-conclusion/zydelig-epar-scientific-conclusions_hu.pdf)

Malti (MT) (95.03 KB - PDF)

**First published:**

21/11/2016

**Last updated:**

21/11/2016

[View](/mt/documents/scientific-conclusion/zydelig-epar-scientific-conclusions_mt.pdf)

Nederlands (NL) (48.98 KB - PDF)

**First published:**

21/11/2016

**Last updated:**

21/11/2016

[View](/nl/documents/scientific-conclusion/zydelig-epar-scientific-conclusions_nl.pdf)

polski (PL) (82.67 KB - PDF)

**First published:**

21/11/2016

**Last updated:**

21/11/2016

[View](/pl/documents/scientific-conclusion/zydelig-epar-scientific-conclusions_pl.pdf)

português (PT) (48.83 KB - PDF)

**First published:**

21/11/2016

**Last updated:**

21/11/2016

[View](/pt/documents/scientific-conclusion/zydelig-epar-scientific-conclusions_pt.pdf)

română (RO) (90.82 KB - PDF)

**First published:**

21/11/2016

**Last updated:**

21/11/2016

[View](/ro/documents/scientific-conclusion/zydelig-epar-scientific-conclusions_ro.pdf)

slovenčina (SK) (88.67 KB - PDF)

**First published:**

21/11/2016

**Last updated:**

21/11/2016

[View](/sk/documents/scientific-conclusion/zydelig-epar-scientific-conclusions_sk.pdf)

slovenščina (SL) (86.75 KB - PDF)

**First published:**

21/11/2016

**Last updated:**

21/11/2016

[View](/sl/documents/scientific-conclusion/zydelig-epar-scientific-conclusions_sl.pdf)

Suomi (FI) (47.64 KB - PDF)

**First published:**

21/11/2016

**Last updated:**

21/11/2016

[View](/fi/documents/scientific-conclusion/zydelig-epar-scientific-conclusions_fi.pdf)

svenska (SV) (48.5 KB - PDF)

**First published:**

21/11/2016

**Last updated:**

21/11/2016

[View](/sv/documents/scientific-conclusion/zydelig-epar-scientific-conclusions_sv.pdf)

Zydelig-H-C-003843-II-0011 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/657576/2016

English (EN) (3.04 MB - PDF)

**First published:** 14/11/2016

**Last updated:** 14/11/2016

[View](/en/documents/variation-report/zydelig-h-c-003843-ii-0011-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Zydelig

Adopted

Reference Number: EMA/CHMP/500725/2016

English (EN) (76.18 KB - PDF)

**First published:** 22/07/2016

**Last updated:** 22/07/2016

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zydelig_en.pdf-0)

CHMP post-authorisation summary of positive opinion for Zydelig

Adopted

Reference Number: EMA/108191/2016

English (EN) (73.17 KB - PDF)

**First published:** 26/02/2016

**Last updated:** 26/02/2016

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zydelig_en.pdf)

## Initial marketing authorisation documents

Zydelig : EPAR - Public assessment report

Adopted

Reference Number: EMEA/CHMP/324336/2014

English (EN) (3.56 MB - PDF)

**First published:** 14/10/2014

**Last updated:** 14/10/2014

[View](/en/documents/assessment-report/zydelig-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Zydelig

Adopted

Reference Number: EMA/CHMP/338526/2014

English (EN) (81.27 KB - PDF)

**First published:** 25/07/2014

**Last updated:** 25/07/2014

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-zydelig_en.pdf)

#### News on Zydelig

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-february-2018) 23/02/2018

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2016) 22/07/2016

[CHMP confirms recommendations for use of Zydelig](/en/news/chmp-confirms-recommendations-use-zydelig) 22/07/2016

[PRAC concludes review of Zydelig and issues updated recommendations for use](/en/news/prac-concludes-review-zydelig-issues-updated-recommendations-use) 08/07/2016

[EMA recommends new safety measures for Zydelig](/en/news/ema-recommends-new-safety-measures-zydelig) 18/03/2016

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 14-17 March 2016](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-14-17-march-2016) 18/03/2016

[EMA reviews cancer medicine Zydelig](/en/news/ema-reviews-cancer-medicine-zydelig) 11/03/2016

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 February 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-february-2016) 26/02/2016

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 July 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-july-2014) 25/07/2014

[European Medicines Agency recommends approval of two new treatment options for rare cancers](/en/news/european-medicines-agency-recommends-approval-two-new-treatment-options-rare-cancers) 25/07/2014

#### More information on Zydelig

- [EMEA-001350-PIP02-13-M04 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001350-pip02-13-m04)
- [Zydelig - referral](/en/medicines/human/referrals/zydelig)
- [Zydelig - withdrawal of application for variation to marketing authorisation](/en/medicines/human/variation/zydelig)
- [Risk Evaluation and Mitigation Strategy (REMS) Assessment Protocol - Zydelig (idelalisib) tablets (Zydelig REMS KAB) - post-authorisation study](https://catalogues.ema.europa.eu/study/20922)
- [Non-interventional retrospective study evaluating the real-life idelalisib use in the population enrolled in the French cohort Temporary Authorization for Use (ATUc) in Chronic Lymphocytic Leukemia (CLL) and indolent Non-Hodgkin Lymphoma (iNHL) (REALIST) - post-authorisation study](https://catalogues.ema.europa.eu/study/30894)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 21/10/2024

## Share this page

[Back to top](#main-content)